HFpEF is associated with defects in myocardial metabolism and translation, particularly in patients with severe obesity, suggesting potential therapeutic targets.
Integrative proteomics, transcriptomics, and pathway analysis supports a defect in both metabolism and translation in HFpEF. Patients with HFpEF with more distinct proteomic signatures from control more often had severe obesity, supporting therapeutic efforts targeting metabolism and translation, particularly in this subgroup.
Jani et al. (Thu,) studied this question.